6/29/2020 7:38:08 AM
Sol-Gel Technologies Announces Agreements With Perrigo Company For Three New Generic Product Candidates
1/2/2020 7:32:20 AM
Sol-Gel Begins SGT-210 Phase 1 Proof Of Concept Study In Palmoplantar Keratoderma
12/30/2019 7:06:56 AM
Sol-Gel Announces Positive Top-Line Phase 3 Trial Results Of Twyneo For Acne Vulgaris
8/8/2019 8:14:17 AM
Sol-Gel Announces Pricing Of Public Offering Of 1.25 Mln Shares At $8.00/Shr
7/8/2019 7:08:48 AM
Sol-Gel Announces Positive Top-Line Results From Epsolay Phase 3 Program In Papulopustular Rosacea
2/6/2019 9:24:16 AM
Sol-Gel Announces FDA Approval For Perrigo’s Generic Acyclovir Cream, 5%
2/6/2019 8:57:23 AM
Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Zovirax Cream 5%
12/17/2018 7:07:23 AM
Sol-Gel Technologies Begins Pivotal Phase III Clinical Program Of TWIN For Treatment Of Acne Vulgaris
9/13/2018 4:08:44 PM
Sol-Gel Technologies Names Jonathan Siegel To Board Of Directors
8/15/2018 4:11:21 PM
Sol-Gel Technologies Announces Collaborative Agreement For Generic Product With Perrigo
8/8/2018 7:06:51 AM
Sol-Gel Technologies Q2 Loss $6.9 Mln Vs Loss $6.2 Mln Last Year